Bazaar - Dr. Marina Peredo: "The Future of Beauty"

Now in Phase 2 clinical trials, Lipo-202 shrinks abdominal fat cells with targeted injections of the drug salmeterol xinafoate.

New York, NY
 – April 15, 2014  –– 

Once injected, the drug activates receptors within fat cells and triggers the breakdown of triglycerides, causing the cells to lose volume (translation: a flatter stomach). "Even though liposuction has improved vastly over the years, this will be perfect for women who don't want invasive surgery; there's no bruising and no downtime," said Marina Peredo, MD, Assistant Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai. "I can do the entire area in three minutes." Learn more